A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)

Completed · Phase 3

Conditions studied: Iron Deficiency Anemia

In brief

To evaluate the safety of 1.020 grams (g) of intravenous (IV) ferumoxytol compared to 1.500 g of IV ferric carboxymaltose (FCM).

Key facts

Study ID
NCT02694978
Run by
AMAG Pharmaceuticals, Inc.
People needed
2014
Starts
2016-02-29
Expected to finish
2017-07-17
Last updated by the study team
2023-07-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.